Table 2 A review of past cases and our case on drug susceptibility and clinical features of M. mageritense-infected cases

Age

60’s

40’s

66

77

5

44

Sex

Male

Male

Male

Male

Girl

Female

Underlying condition

ESKD on peritoneal dialysis

None specified

None specified

COPD, CAD

Acute encephalopathy, adrenal insufficiency

Breast cancer

Site of infection

Skin and peritoneum

Parotid gland

Prosthetic joint

Pleura

Soft tissue

Soft tissue and CVP

MIC (μg/mL)

Breakpoint of resistance (μg/mL)

 IPM

 < 0.5

1

4

 < 0.5

0.5

 < 2

 ≥ 32

 AMK

2

 > 64

8

4

32

 < 8

 ≥ 64

 CAM

0.25

N/A

 > 32

16

 > 512

 > 8

 ≥ 8

 TOB

4

N/A

N/A

 > 16

 > 16

N/A

 ≥ 8

 LZD

1

2

 < 1

 < 4

8

 < 4

 ≥ 32

 CPFX

 < 0.12

0.5

32

 < 0.5

0.25

1

 ≥ 4

 MFLX

 < 0.06

N/A

 < 0.25

 < 0.25

0.19

 < 1

 ≥ 4

 MINO

0.5

N/A

 < 1

2

4

N/A

 ≥ 8

 ST

 < 0.25/4.3

2

1/19

 < 2

 > 80

 > 4

 ≥ 4/76

Antibiotics

IPM

LVFX

CPFX

IPM

Tosufloxacin

AMK

AMK

ST

ST

LVFX

LZD

CPFX

CAM

AMK

IPM

Surgical intervention

Catheter removal

Parotid gland excision

Prosthetic joint explantation

Pleural fluid drainage

Abscess drainage

CVP removal and debridement

Outcome

Death due to peritonitis

Cured

Cured

Death due to aspiration pneumonia

Cured

Cured

Reference number

Present case

[5]

[6]

[7]

[8]

[9]